ArticlePLoS pathogens2023
Group B Streptococcus and diabetes: Finding the sweet spot.
Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Environmentally activatable hydrogel for spatiotemporally programmed nitric oxide delivery for diabetic wound healing.Materials today. Bio · 2026Article
- Human neutrophils recognize group B streptococciFrontiers in immunology · 2026Article
- Epidemiologic characteristics of invasive group B streptococcal infections caused by rare serotypes among adults in the United States, 2007-2023.PLOS global public health · 2026Article
- Delineating markers of disease-disease interaction: a systematic methodology and its application to multiple diabetes-helminth cohorts.BMC bioinformatics · 2025Article
- Suppurative Spondylitis Misdiagnosed as Endplate Inflammation: A Rare Case Report.Clinical case reports · 2025Article
- Maternal and neonatal outcomes of Group B Streptococcus colonization: a retrospective study.BMC infectious diseases · 2025Article
- Human oral microbiome and its influence on mental health and brain disorders.AIMS microbiology · 2025Review
- Structural and genomic insights into erythromycin and clindamycin resistance of group BFrontiers in microbiology · 2025Article
- Triple threat: how diabetes results in worsened bacterial infections.Infection and immunity · 2024Review
- Re-framing the importance of Group BInfection and immunity · 2024Review
- Group BEuropean journal of case reports in internal medicine · 2024Article
- Engagement of αFrontiers in microbiology · 2024Article
- The impact of nutritional immunity on Group B streptococcal pathogenesis during wound infection.mBio · 2023Article
- Unveiling the Human Gastrointestinal Tract Microbiome: The Past, Present, and Future of Metagenomics.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.